January 6, 2020 Clinical Research/Diagn. M&A, Partnerships

Abcam announces successful acquisition of Expedeon’s Proteomics and Immunology business, enhancing its conjugation capability

Includes leading protein conjugation technologies and industry brands Lightning-Link® and CaptSureTM Opportunity to combine Expedeon and Abcam’s technologies to create new products to support research and diagnostic development Cambridge, UK, -06 January 2020: Abcam plc, a global innovator in life science reagents and tools, is pleased to announce the successful completion of the acquisition of Expedeon’s Proteomics... Read more

November 11, 2019 Clinical Research/Diagn. M&A, Partnerships

Abcam agrees to acquire Expedeon’s Proteomics and Immunology business, expanding offerings into the fast-growing conjugation segment

Acquisition of leading protein conjugation technologies and products with wellknown industry brands, including Lightning-Link® and CaptSureTM Complementary to Abcam’s existing antibody and multiplex growth strategy, with high customer overlap Acquisition expected to be accretive from the first full year of ownership (FY21)1 and to deliver a ROIC (pretax) ahead of the Group’s WACC by the... Read more